Cross-industrial applications of organotypic models.

Recent advances in microphysiological systems (MPS) promise a global paradigm shift in drug development, diagnostics, disease prevention, and therapy. The expectation is that these systems will model healthy and various diseased stages and disease progression to predict toxicity, immunogenicity, ADME profiles, and treatment efficacies. MPS will provide unprecedented human-like physiological properties of in vitro models, enabling their routine application in the pharma industry and thus reducing drug development costs by lowering the attrition rate of compounds. We showcased MPS application diversity across different industries during the TEDD Annual Meeting on 14th October 2021 in Wädenswil, Switzerland. The goal was to promote cross-sectoral collaboration of academia and industry to further pave the way for developing next-generation MPS based on 3D cell culture, organoid, and organ-on-chip technology and their widespread exploitation. To enable visionary projects and radical innovations, we covered multidisciplinary fields and connected different industry sectors, like pharma, medtech, biotech, cosmetics, diagnostics, fragrances, and food, with each other.